ArticleFrontiers in immunology2026
Establishment of a novel lupus mesenteric vasculitis mouse model and exploration of its exacerbation mechanisms.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lupus mesenteric vasculitis (LMV) is a gastrointestinal lesion primarily caused by vasculitis associated with systemic lupus erythematosus (SLE). In our preliminary experiments, we found that NZBWF1 (BWF1) mice, a spontaneous SLE mouse model, developed bloody stools when treated with imiquimod, a Toll-like receptor (TLR) 7 agonist. Therefore, in this study, we investigated the effects of the continuous application of a TLR7/8 agonist resiquimod (R848) on the gastrointestinal tract in BWF1 mice. To address this, 8-week-old female BWF1 mice were treated with R848 three times weekly for up to 6 weeks. We found that R848-treated mice developed intestinal vasculitis. In addition, these mice exhibited significantly increased serum autoantibody levels and accelerated SLE pathology. Because these symptoms closely resemble human LMV pathology, we established this as a novel inducible LMV mouse model. To elucidate the mechanisms underlying the onset and exacerbation of LMV, we analyzed changes in the intestinal environment. LMV-induced mice showed altered intestinal microbiota and increased fecal levels of propionic acid, an intestinal microbiota metabolite. To investigate the effect of bacteria on LMV pathogenesis, we treated LMV-induced mice with broad-spectrum antibiotics and found that this treatment tended to suppress LMV pathology early in the induction period. Furthermore, propionate administration appeared to attenuate intestinal vasculitis in these mice. Thus, we found that increased intestinal propionate contributes to attenuating LMV pathology. In conclusion, we established an inducible LMV mouse model by R848 treatment of BWF1 mice. Using this induced LMV mouse model, the pathophysiology of LMV can be analyzed in detail. Additionally, our findings suggest that bacteria influence the induction and exacerbation of LMV pathogenesis, and that intestinal propionate may be involved in maintaining homeostasis. In the future, this LMV mouse model may contribute to the development of new diagnostic and therapeutic methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.